12 Month Price Forecast For VRTX
Distance to VRTX Price Forecasts
VRTX Price Momentum
🤔 Considering Vertex (VRTX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 9:33 PM UTC
VRTX Analyst Ratings & Price Targets
Based on our analysis of 42 Wall Street analysts, VRTX has a consensus that is bullish. The median price target is $538.00, with forecasts ranging from $325.00 to $602.00. Currently, there are 23 Buy ratings, 10 Hold ratings, and 3 Sell ratings.
With VRTX currently trading at $464.12, the median price forecast suggests a 15.9% upside. The most optimistic forecast comes from at , projecting a 29.7% upside, while Brian Skorney at Baird provides the most conservative target, suggesting a -30.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRTX Analyst Consensus
VRTX Price Target Range
Latest VRTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 9, 2024 | Jefferies | Michael Yee | Buy | Upgrade | $550.00 |
| Nov 14, 2024 | Citigroup | Geoff Meacham | Buy | Initiates | $575.00 |
| Nov 6, 2024 | Canaccord Genuity | Whitney Ijem | Sell | Maintains | $408.00 |
| Nov 5, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $451.00 |
| Nov 5, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $503.00 |
| Nov 5, 2024 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $476.00 |
| Nov 5, 2024 | UBS | Colin Bristow | Buy | Maintains | $586.00 |
| Nov 5, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $480.00 |
| Nov 5, 2024 | Scotiabank | Greg Harrison | Sector Perform | Maintains | $486.00 |
| Oct 30, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $540.00 |
| Oct 21, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $600.00 |
| Oct 17, 2024 | UBS | Colin Bristow | Buy | Maintains | $562.00 |
| Oct 16, 2024 | Scotiabank | Greg Harrison | Sector Perform | Initiates | $480.00 |
| Oct 14, 2024 | B of A Securities | Ying Huang | Buy | Maintains | $541.00 |
| Oct 10, 2024 | Raymond James | Danielle Brill | Market Perform | Reinstates | $0.00 |
| Oct 9, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $437.00 |
| Oct 8, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $480.00 |
| Oct 4, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $425.00 |
| Oct 1, 2024 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $474.00 |
| Sep 19, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Reiterates | $431.00 |
Vertex Pharmaceuticals Inc (VRTX) Financial Data
Vertex Pharmaceuticals Inc has a market capitalization of $120.60B with a P/E ratio of 32.8x. The company generates $10.63B in trailing twelve-month revenue with a -4.5% profit margin.
Revenue growth is +11.6% quarter-over-quarter, while maintaining an operating margin of +40.8% and return on equity of -3.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Vertex Pharmaceuticals Inc (VRTX) Company Overview
About Vertex Pharmaceuticals Inc
Develops therapies for cystic fibrosis and other diseases.
The company generates revenue by developing and commercializing specialized therapies for cystic fibrosis (CF) and other serious diseases. It markets several FDA-approved drugs for CF and has a diverse pipeline of therapies in various stages of clinical trials targeting conditions like sickle cell disease, pain management, and cancer.
Vertex Pharmaceuticals has established collaborations with prominent biotech companies, enhancing its research capabilities and therapeutic development. Founded in 1989 and based in Boston, Massachusetts, the company is positioned as a leader in the biotechnology sector with a strong focus on innovative treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5,400
CEO
Dr. Reshma Kewalramani FASN, M.D.
Country
United States
IPO Year
1991
Website
www.vrtx.comVertex Pharmaceuticals Inc (VRTX) Latest News & Analysis
The Ultimate Biotech Stock to Buy With $500 Right Now
1 day agoBiotech stocks are characterized by high volatility and risk, making them a challenging investment choice for some investors.
Biotech stocks present high volatility and risk, impacting investment strategies and potential returns, which may deter risk-averse investors from entering this sector.
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
2 days agoVertex Pharmaceuticals' CF franchise, led by TRIKAFTA's $2.77bn Q3 revenues, remains strong. Upcoming Vanzacaftor therapy and promising Casgevy for Sickle Cell Disease suggest substantial growth.
Vertex Pharmaceuticals' robust CF franchise, strong Q3 revenues, and promising new therapies signal continued growth potential, which could enhance investor confidence and drive stock performance.
Biotech Roundup: 3 Stocks to Watch
2 days agoInvestors are considering potential shifts in the biotech sector following President-elect Trump's selection of Martin Makary as FDA commissioner.
Changes in FDA leadership can impact regulatory policies, potentially affecting drug approvals and biotech innovation, influencing stock prices and investment strategies in the biotech sector.
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
4 days agoJefferies upgraded Vertex Pharmaceuticals (VRTX), highlighting strong cystic fibrosis sales and potential growth from a new LNP/mRNA therapy and "triple pill" regimens, estimating a $1 billion opportunity.
Jefferies' upgrade of Vertex Pharmaceuticals highlights strong growth potential from its cystic fibrosis treatments and promising new therapies, which could enhance the company's market value and investor returns.
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
3 days agoVertex Pharmaceuticals (VRTX) closed at $469.29, down 0.99% from the previous trading day.
A 0.99% decline in Vertex Pharmaceuticals' stock price could signal market sentiment shifts, impacting investor confidence and potential future trading strategies.
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
5 days agoVertex Pharmaceuticals reported positive long-term data for CASGEVY™, a CRISPR/Cas9 gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, at the ASH Annual Meeting.
Vertex Pharmaceuticals' positive long-term data for CASGEVY could enhance its market position in gene therapy, potentially boosting stock performance and investor confidence in future growth.
Frequently Asked Questions About VRTX Stock
What is Vertex Pharmaceuticals Inc's (VRTX) stock forecast for 2025?
Based on our analysis of 42 Wall Street analysts, Vertex Pharmaceuticals Inc (VRTX) has a median price target of $538.00. The highest price target is $602.00 and the lowest is $325.00.
Is VRTX stock a good investment in 2025?
According to current analyst ratings, VRTX has 23 Buy ratings, 10 Hold ratings, and 3 Sell ratings. The stock is currently trading at $464.12. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for VRTX stock?
Wall Street analysts predict VRTX stock could reach $538.00 in the next 12 months. This represents a 15.9% increase from the current price of $464.12. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vertex Pharmaceuticals Inc's business model?
The company generates revenue by developing and commercializing specialized therapies for cystic fibrosis (CF) and other serious diseases. It markets several FDA-approved drugs for CF and has a diverse pipeline of therapies in various stages of clinical trials targeting conditions like sickle cell disease, pain management, and cancer.
What is the highest forecasted price for VRTX Vertex Pharmaceuticals Inc?
The highest price target for VRTX is $602.00 from at , which represents a 29.7% increase from the current price of $464.12.
What is the lowest forecasted price for VRTX Vertex Pharmaceuticals Inc?
The lowest price target for VRTX is $325.00 from Brian Skorney at Baird, which represents a -30.0% decrease from the current price of $464.12.
What is the overall VRTX consensus from analysts for Vertex Pharmaceuticals Inc?
The overall analyst consensus for VRTX is bullish. Out of 42 Wall Street analysts, 23 rate it as Buy, 10 as Hold, and 3 as Sell, with a median price target of $538.00.
How accurate are VRTX stock price projections?
Stock price projections, including those for Vertex Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
